Fig 2.

Event-free survival (EFS), disease-free survival (DFS), and overall survival (OS) curves overall and by regimen. (A) EFS and OS curves for all patients with T-cell acute lymphoblastic leukemia; 5-year EFS and OS rates were 83.8% (81.2% to 86.4%) and 89.5% (87.4% to 91.7%), respectively. (B) DFS curves for Capizzi-style escalating intravenous methotrexate (C-MTX) versus high-dose methotrexate (HDMTX) randomly assigned cohorts; 5-year DFS rate was 91.5% (88.1% to 94.8%) for C-MTX and 85.3% (81.0% to 89.5%) for HDMTX. (C) OS curves for C-MTX versus HDMTX randomly assigned cohorts; 5-year OS was 93.7% (90.8% to 96.6%) for C-MTX and 89.4% (85.7% to 93.2%) for HDMTX.